Magenta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGTA research report →
About the company
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody.
- CEO
- Stephen F. Mahoney MBA
- IPO
- 2018
- Employees
- 67
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $42.44M
- P/E
- -0.02
- P/S
- 48.62
- P/B
- 0.00
- EV/EBITDA
- 8.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -21911.68%
- Net Margin
- -19892.33%
- ROE
- -27.30%
- ROIC
- -15.82%
- Revenue
- $2.04M · -67.35%
- Net Income
- $-162,337,000 · -91.05%
- EPS
- $0.00 · 100.00%
- Op Income
- $-177,933,000
- FCF YoY
- -65.13%
- 52W High
- $1.81
- 52W Low
- $0.32
- 50D MA
- $0.78
- 200D MA
- $0.73
- Beta
- 2.11
- Avg Volume
- 247.98K
Get TickerSpark's AI analysis on MGTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 23 | Fairmount Funds Management LLC | buy | 24,670 |
| Sep 26, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 22, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 21, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 19, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 11, 23 | Meng Lei | other | 6,500 |
| Sep 11, 23 | Meng Lei | other | 0 |
| Sep 11, 23 | Violin Jonathan | other | 6,500 |
| Sep 13, 23 | Fairmount Funds Management LLC | buy | 9,367 |
| Sep 12, 23 | Fairmount Funds Management LLC | buy | 14,887 |
Our MGTA coverage
Recent articles, reports, and earnings notes.
No research on MGTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGTA report →Similar companies
Peers in the same neighborhood.